Tissue Regenix (TRX) – cheapest biotech on AIM?!15 Nov 2019 14:19
I also suspect that institutions and individual investors will be queuing up to inject capital as the current depressed valuation. Worst-case scenario: I believe that in a fire sale, Tissue Regenix’s IP could potentially be sold for a great deal more than the current enterprise value.